Individuals who form kidney stones are at increased risk for myocardial infarction (MI) independent of CKD and other risk factors, according to researchers.

Active surveillance may be a suitable option for many men with low-risk prostate cancer (PCa), Swedish researchers concluded.

SAN FRANCISCO—Initiating statin therapy after radical prostatectomy (RP) may decrease the risk of biochemical recurrence of prostate cancer, new data suggest.

The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects, according to Julia B. Lewis, MD, of the division of nephrology and hypertension at Vanderbilt University School of Medicine in Nashville.

Deaths from prostate cancer (PCa) fell by almost half after 14 years of biennial screening, according to data from a Swedish study.

A study of testosterone supplementation in older men was terminated after daily application of a testosterone gel was associated with a significantly increased risk of cardiovascular (CV) adverse events.

Low socioeconomic status (SES) increases blacks' risk of developing CKD nearly twofold, but does not increase the risk in whites, according to a recent report in the American Journal of Kidney Diseases (2010;55:977-980).

A high resting heart rate and low beat-to-beat heart rate variability raises the odds of developing kidney disease, according to a study that examined data from 13,241 participants in the Atherosclerosis Risk in Communities study.

Acupuncture may be an effective treatment for hot flashes in men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa), according to findings published online in Urology.

CHICAGO—Tasquinimod, a novel biologic agent, may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrate-resistant prostate cancer (CRCP), according to a new study presented at the American Society of Clinical Oncology annual meeting.